| dc.contributor.author | Farjadian, Shirin | en_US |
| dc.contributor.author | Tabebordbar, Maryam | en_US |
| dc.contributor.author | Mokhtari, Maral | en_US |
| dc.contributor.author | Safaei, Akbar | en_US |
| dc.contributor.author | Malekzadeh, Mahyar | en_US |
| dc.contributor.author | Ghaderi, Abbas | en_US |
| dc.date.accessioned | 1399-07-08T18:03:51Z | fa_IR |
| dc.date.accessioned | 2020-09-29T18:03:51Z | |
| dc.date.available | 1399-07-08T18:03:51Z | fa_IR |
| dc.date.available | 2020-09-29T18:03:51Z | |
| dc.date.issued | 2018-10-01 | en_US |
| dc.date.issued | 1397-07-09 | fa_IR |
| dc.date.submitted | 2017-07-02 | en_US |
| dc.date.submitted | 1396-04-11 | fa_IR |
| dc.identifier.citation | Farjadian, Shirin, Tabebordbar, Maryam, Mokhtari, Maral, Safaei, Akbar, Malekzadeh, Mahyar, Ghaderi, Abbas. (2018). HLA-G Expression in Tumor Tissues and Soluble HLA-G Plasma Levels in Patients with Gastrointestinal Cancer. Asian Pacific Journal of Cancer Prevention, 19(10), 2731-2735. doi: 10.22034/APJCP.2018.19.10.2731 | en_US |
| dc.identifier.issn | 1513-7368 | |
| dc.identifier.issn | 2476-762X | |
| dc.identifier.uri | https://dx.doi.org/10.22034/APJCP.2018.19.10.2731 | |
| dc.identifier.uri | http://journal.waocp.org/article_69073.html | |
| dc.identifier.uri | https://iranjournals.nlai.ir/handle/123456789/35404 | |
| dc.description.abstract | Background: Overexpression of human leukocyte antigen G (HLA-G) and increased plasma levels of soluble<br />HLA-G (sHLA-G) have been reported in different human malignancies, and are believed to be involved in tumor immune<br />evasion. Objectives: This study was designed to evaluate the expression of HLA-G in tumor tissues and the plasma<br />levels of sHLA-G in patients with gastrointestinal cancer, and to determine their associations with clinicopathological<br />factors. The link between Helicobacter pylori infection and increased HLA-G expression or sHLA-G levels was also<br />investigated in patients with gastric cancer. Methods: HLA-G expression was investigated in tumor tissues from 100<br />patients with gastric and colorectal adenocarcinoma using immunohistochemistry test, and plasma levels of sHLA-G<br />were measured in 82 patients with ELISA method. The presence of H. pylori genome was investigated in tumor<br />tissues from 25 patients with gastric cancer by PCR method. Results: HLA-G expression was observed in 43% of<br />colorectal cancers and 34.6% of gastric cancers, and was not related with any of the clinicopathological factors. There<br />was a significant correlation between increased sHLA-G level and stage I tumors. Eight of 25 (32%) gastric cancer<br />specimens were positive for H. pylori, of which 3 samples were positive for HLA-G. Soluble HLA-G levels were above<br />the cut-off value in all H. pylori-positive patients. Conclusion: Plasma levels of sHLA-G were significantly increased<br />in our patients with a sensitivity of 89% and a specificity of 62%. Soluble HLA-G level can be considered a useful<br />indicator for the early diagnosis of gastric and colorectal adenocarcinoma. | en_US |
| dc.format.extent | 423 | |
| dc.format.mimetype | application/pdf | |
| dc.language | English | |
| dc.language.iso | en_US | |
| dc.publisher | West Asia Organization for Cancer Prevention (WAOCP) | en_US |
| dc.relation.ispartof | Asian Pacific Journal of Cancer Prevention | en_US |
| dc.relation.isversionof | https://dx.doi.org/10.22034/APJCP.2018.19.10.2731 | |
| dc.subject | HLA-G | en_US |
| dc.subject | sHLA-G | en_US |
| dc.subject | colorectal cancer | en_US |
| dc.subject | Gastric cancer | en_US |
| dc.subject | Helicobacter pylori | en_US |
| dc.subject | Immunology | en_US |
| dc.title | HLA-G Expression in Tumor Tissues and Soluble HLA-G Plasma Levels in Patients with Gastrointestinal Cancer | en_US |
| dc.type | Text | en_US |
| dc.type | Research Articles | en_US |
| dc.contributor.department | Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. | en_US |
| dc.contributor.department | Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. | en_US |
| dc.contributor.department | Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran. | en_US |
| dc.contributor.department | Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran. | en_US |
| dc.contributor.department | Institute for Cancer Research, Shiraz University of Medical Sciences,
Shiraz, Iran. | en_US |
| dc.contributor.department | Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. | en_US |
| dc.citation.volume | 19 | |
| dc.citation.issue | 10 | |
| dc.citation.spage | 2731 | |
| dc.citation.epage | 2735 | |